Background/Objectives: Multiple primary malignancies (MPMs) are defined as the occurrence of two or more independent primary tumors in the same patient, histologically distinct and not of metastatic origin. Patients treated for Hodgkin’s lymphoma (HL) carry an increased risk of developing secondary malignancies, especially after chemotherapy and radiotherapy. The synchronous occurrence of breast and kidney carcinoma in this population is extremely rare. Methods: We present a 41-year-old female patient with a history of HL treated at the age of 23 with ABVD chemotherapy and supradiaphragmatic radiotherapy. Results: During staging for a newly diagnosed breast tumor (ER+/PR+/HER2+, pT1cN0), an incidental renal mass was identified and histologically confirmed as clear cell renal cell carcinoma (pT1aNxMx, G2). A multidisciplinary team performed simultaneous partial breast resection with sentinel lymph node biopsy and nephrectomy. The postoperative course was uneventful, and adjuvant systemic therapy was initiated according to oncological guidelines. Conclusions: Synchronous malignancies in HL survivors pose a clinical challenge, as they must be distinguished from metastatic disease and require coordinated therapeutic planning. Risk factors include prior radiotherapy, chemotherapy, genetic predisposition, and family history. This case highlights the importance of long-term surveillance of HL survivors, particularly young women, due to their elevated risk of secondary malignancies. Synchronous breast and kidney carcinomas after HL therapy are extremely rare and demand an integrated multidisciplinary approach. Early recognition and coordinated therapy are crucial for optimizing outcomes and contributing to a better understanding of the etiology and pathogenesis of multiple primary malignancies.

Introduction: Breast sarcomas (BS) are rare malignant tumors with aggressive behavior and limited evidence guiding outcome assessment. Data on distant metastasis-free interval (DMFI) in this population are scarce. This study aimed to describe oncologic outcomes and clinicopathologic characteristics in patients with BS treated with curative intent. Methods: Patients with primary or secondary breast sarcoma treated at a single tertiary cancer center between 2013 and 2025 were retrospectively analyzed. Patients with metastatic disease at diagnosis were excluded. DMFI was the primary endpoint, and OS was the endpoint. Survival outcomes were estimated using Kaplan-Meier methodology and presented descriptively. Results: Twenty-six patients met the inclusion criteria. Angiosarcoma was the most common histologic subtype, predominantly occurring as secondary disease after prior breast radiotherapy. Median DMFI was not reached during follow-up, with 71.5% of patients remaining metastasis-free at 3 years, whereas median OS was 31 months with a 3-year OS of 46.9%. Patients with higher pathological T stage, larger tumors, tumor necrosis, younger age, and narrower resection margins tended to demonstrate shorter DMFI. Differences in overall survival were most pronounced according to resection margin status. Conclusions: Tumor burden-related factors, tumor necrosis, and surgical margin width showed clinically relevant differences in metastasis-related outcomes and survival in breast sarcoma. Adequate surgical resection remains critical in this rare and heterogeneous disease.